Adverse Neuropsychiatric Events Associated with Varenicline Use in Veterans: A Case Series

Cantrell, Matthew; Argo, Tami R.; Haak, Lauren; Janney, Laurel

doi:10.3109/01612840.2012.692463

Cited by 6 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reviewed articles and systematically abstracted article information into databases that summarized data collection and methods, sample and setting, results/data, and conclusions. Most of the articles reviewed were cross‐sectional studies (34%), RCTs (18%), or nonsystematic reviews (11%) (Table ; for an expanded version of Table , see Supporting Information Tables 1‐3 [see online supporting information]) …”

Section: Methodsmentioning

confidence: 99%

Cancer screening, prevention, and treatment in people with mental illness

Weinstein

Stefancic

Cunningham

et al. 2015

CA A Cancer J Clinicians

View full text Add to dashboard Cite

People with mental illness die decades earlier in our country when compared to the general public Most of this disparity is related to preventable and treatable chronic conditions, with many studies finding cancer as the second leading cause of death. Individual lifestyle factors, such as smoking or limited adherence to treatment, are often cited as highly significant issues in shaping risk among persons with mental illness. However, many contextual or systems-level factors exacerbate these individual factors and may fundamentally drive health disparities among people with mental illness. We conducted an integrative review in order to summarize the empirical literature on cancer prevention, screening, and treatment for people with mental illness. While multiple interventions are being developed and tested to address tobacco dependence and obesity in these populations, the evidence for effectiveness is quite limited, and essentially all prevention interventions focus at the individual level. This review was able to find only one published article describing evidence-based interventions to promote cancer screening and improve cancer treatment in people with mental illness. Based on our review of the literature and the experience and expertise of the authors, we conclude each section with suggestions at the individual, interpersonal, organizational, community, and policy level that may improve cancer prevention, screening, and treatment in people with mental illness.

show abstract

Section: Methodsmentioning

confidence: 99%

Cancer screening, prevention, and treatment in people with mental illness

Weinstein

Stefancic

Cunningham

et al. 2015

CA A Cancer J Clinicians

View full text Add to dashboard Cite

show abstract

“…Over the study period, receipt of varenicline reached its peak in 2007 and then fell sharply in 2008 (4.5% among PWH and 4.8% among PWoH to 2.9% and 2.8%) after the FDA issued a warning for its use. The warning explicitly noted that changes in mood, behavior, and suicidal ideation had been reported in patients attempting to quit smoking while using varenicline [ 28 ]. For this reason and situations specifically involving veterans, the VHA previously considered varenicline a second-line treatment and had strictly controlled its use during the study period.…”

Section: Discussionmentioning

confidence: 99%

Receipt of Smoking Cessation Medications Among People With and Without Human Immunodeficiency Virus in the Veterans Aging Cohort Study (2003–2018)

Crothers

McGinnis

Chan

et al. 2023

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background Nicotine replacement therapy (NRT), bupropion, and varenicline are smoking cessation medications (SCM) shown to be similarly effective in people with and without HIV (PWH and PWoH, respectively), though rates of receipt of these medications are unknown. Methods We identified patients in the Veterans Aging Cohort Study (VACS) with EHR-documented current smoking using clinical reminder data for tobacco use (2003-2018). We measured receipt of SCM using VA pharmacy data for outpatient prescriptions filled 0-365 days following current smoking documentation. We used log-linear Poisson-modified regression models to evaluate the relative risk (RR) for receiving SCM by HIV status, the annual rate of receipt, and rate difference among PWH relative to PWoH. Results The sample included 92,632 patients (29,086 PWH), reflecting 381,637 documentations of current smoking. From 2003 to 2018, the proportion receiving SCM increased from 15% to 34% for PWH and from 17% to 32% among PWoH. There was no statistical difference in likelihood of receiving SCM by HIV status (RR 1.010, 95% CI 0.994-1.026). Annual rates of receiving SCM increased for PWH by 4.3% per year (RR 1.043, 95% CI 1.040-1.047) and for PWoH by 3.7% per year (RR 1.037, 95% CI 1.036-1.038; rate difference +0.6% [RR 1.006, 95% CI 1.004-1.009]). Conclusions In a national sample of current smokers, receipt of SCM doubled over the 16-year period, and differences by HIV status were modest. However, fewer than 35% of current smokers receive SCM annually. Efforts to improve SCM receipt should continue for both groups given the known dangers of smoking.

show abstract

Varenicline

2013

Reactions Weekly

View full text Add to dashboard Cite

Adverse Neuropsychiatric Events Associated with Varenicline Use in Veterans: A Case Series

Cited by 6 publications

References 13 publications

Cancer screening, prevention, and treatment in people with mental illness

Cancer screening, prevention, and treatment in people with mental illness

Receipt of Smoking Cessation Medications Among People With and Without Human Immunodeficiency Virus in the Veterans Aging Cohort Study (2003–2018)

Varenicline

Contact Info

Product

Resources

About